SCHEMBL10107534

SCHEMBL10107534

C=C(C)OC(=O)N1CCN(Cc2nc(-c3ccncc3)no2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.61
LMNA P02545 3/20 0.61
MAPK1 P28482 1/20 0.61
SMN1; SMN2 Q16637 4/20 0.59
CYP2D6 P10635 2/20 0.59
HTT P42858 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
KCNH2 Q12809 2/20 0.53
PKM P14618 1/20 0.52
GPR119 Q8TDV5 1/20 0.50
NAMPT P43490 1/20 0.48
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391801 0.84 GPR119 (0.69) KMT2ALMNAMAPK1SMN1; SMN2CYP2D6
SCHEMBL5133503 0.82 KMT2A (0.61) KMT2ALMNAMAPK1SMN1; SMN2CYP2D6
SCHEMBL10107355 0.81 GPR119 (0.52) KMT2ALMNAMAPK1SMN1; SMN2CYP2D6
SCHEMBL10107598 0.81 GPR119 (0.57) KMT2ALMNAMAPK1SMN1; SMN2CYP2D6
SCHEMBL10107592 0.78 GPR119 (0.49) KMT2ALMNAMAPK1SMN1; SMN2CYP2D6
SCHEMBL10107332 0.77 GPR119 (0.60) KMT2ALMNASMN1; SMN2GPR119NPC1
SCHEMBL2759473 0.71 KDM4E (0.43) KMT2ALMNAMAPK1SMN1; SMN2CYP2D6
SCHEMBL10107767 0.69 GPR119 (0.71) LMNASMN1; SMN2GPR119NPC1RAB9A
SCHEMBL13168312 0.69 CYP3A4 (0.65) KMT2AMAPK1SMN1; SMN2CYP2D6CYP1A2
SCHEMBL387143 0.69 GPR119 (0.80) KMT2ALMNAMAPK1SMN1; SMN2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207147-B2 Heterocyclic derivatives as GPCR receptor agonists PROSIDION LIMITED (GB) 2012-06-26 US disclosed
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS GPR119, GCGR, GLP1R KMT2A 2889/4885LMNA 4276/4885MAPK1 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.